Aurora Cannabis Inc. · TSX:ACB
Aurora Cannabis — Q2 2022 Earnings Presentation
7 slides from Aurora Cannabis's earnings presentation, Feb 10, 2022
Slide 1: Fiscal Q2 2022 Supplemental Information
FISCAL Q2 2022 SUPPLEMENTAL INFORMATION FEBRUARY 2022
Slide 2: Disclaimer
Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed
Slide 3: Key Takeaways
3 Key Takeaways Transformation Roadmap to Adjusted EBITDA positive position without depending on revenue growth Plan on Track Actions taken to date result in ~ $60 million in annualized run-rate cost savings Delivered over~ $300 million of annualized expense reductions since February 2020 Medi
Slide 4: Q2 2022 Key Financial Highlights
4 Q2 2022 Key Financial Highlights • Strong Canadian Medical Performance • #1 market share with strong and consistent margins • Direct-to-patient model bypasses provincial distributor • Consistency and product selection the key driver of patient retention in medical versus adult recreational consume
Slide 5: Key Financial Trends
5 Key Financial Trends Materially Reduced SG&A Materially Reduced Capital Investments SG&A and R&D Expense (Excluding Restructuring) ($M) $M $M Capital Expenditures ($M) 80 90 70 80 60 70 60 50 50 40 40 30 30 20 20 10 10 0 0 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 20 Q4 20 Q1 21 Q2 21 Q3
Slide 6: Pathway to Positive Adjusted EBITDA
6 Pathway to Positive Adjusted EBITDA Cost savings map clear pathway to positive Adjusted EBITDA by mid FY23 without depending on revenue growth: • ~$60 million in annualized savings implemented to date • Now expect to realize upper end of $60 to $80 million range in total cost savings mid FY23 60%
Slide 7: Investor Presentation
INVESTOR PRESENTATION Email: aurora@icrinc.com Website: investor.auroramj.com